Workday Stock And 2 Software Picks Backed By Insider Confidence
Global growth signals look uneven, inflation trends are mixed, and central banks are keeping investors on their toes. In this kind of backdrop, many readers are looking for companies where management is financially aligned with shareholders and where analysts still see room for growth. That is exactly what the Fast Growing Stocks With High Insider Ownership screener aims to surface. It focuses on businesses with strong growth potential and confident insider backing. In this article you will see three of the most interesting stocks from that screener and what makes each one worth a closer look.
Workday (WDAY)
Overview: Workday is a US based software company that provides cloud applications that help large organizations run core finance, HR, planning, procurement, and industry specific workflows through a single platform. Its tools are used to manage accounting, payables, expenses, workforce hiring and development, and complex planning for sectors ranging from healthcare and education to technology and government.
Operations: Workday generates about US$9.9b in revenue from cloud applications, with roughly US$7.4b coming from the United States and about US$2.5b from other countries.
Market Cap: US$39.0b
Investors looking at Workday are really looking at a leading cloud platform that is already seeing strong use of AI powered HR and finance products, supported by partnerships across AWS, Google Cloud, Microsoft 365 and fintech players like EarnIn. Reported earnings growth of 73.9% over the past year and net margins of 8.6% indicate that profitability has recently moved in a positive direction, while recent FedRAMP authorization and government focused products provide access to more regulated workloads. At the same time, the stock trades on a higher P/E than the US software industry and relies on external borrowing, and there is competitive and regulatory pressure around AI and data. The overall picture depends on how these strengths and risks balance out over time.
Workday’s accelerating AI adoption and recent profitability shift could be masking a very different risk reward profile than its headline P/E suggests. See how the analysis report for Workday reframes the story precisely where expectations appear most fragile.
Corcept Therapeutics (CORT)
Overview: Corcept Therapeutics is a US biopharmaceutical company that develops cortisol focused drugs to treat severe endocrine, metabolic, neurologic, and cancer related conditions. Its commercial product Korlym targets Cushing’s syndrome, while newer drugs such as relacorilant and Lifyorli extend its reach into both hypercortisolism and platinum resistant ovarian cancer.
Market Cap: US$10.0b
Corcept Therapeutics is attracting attention because it is shifting from relying heavily on a single drug, Korlym, to a broader portfolio that now includes Lifyorli for ovarian cancer and a late stage relacorilant program that could further diversify revenue. Recent quarters show record revenue and raised full year guidance, yet the stock trades with a rich P/S multiple and a Simply Wall St model value of US$36.83 per share versus a US$118.32 price. This difference flags a potential expectations gap. In addition, margin pressure, ongoing Korlym litigation, and long tenured governance contribute to a higher risk profile, tied to a company with strong growth forecasts and multiple upcoming FDA decisions and trial readouts that could materially change the story.
Corcept Therapeutics appears to present an expectations mismatch, with growth ambitions and litigation risk pulling in opposite directions. Get the full picture from the 1 key reward and 1 important warning sign
Klaviyo (KVYO)
Overview: Klaviyo is a Boston based software company that runs a cloud platform helping consumer facing businesses manage marketing, customer relationships, and analytics in one place, using tools like AI assistants, email and mobile messaging, social data, and real time marketing insights.
Operations: Klaviyo generates about US$1.3b in revenue from internet software, with roughly US$778.7m from the United States and the rest spread across Europe, the Asia Pacific region, and other international markets.
Market Cap: US$5.8b
Klaviyo attracts interest because it sits at the crossroads of AI, first party customer data, and e commerce, with a B2C CRM platform that now stretches from marketing automation to customer service. Recent AI launches like Composer and Customer Agent, plus features such as Klaviyo Social and Helpdesk, aim to increase how much existing clients spend over time. The company is still early on its profitability journey and has seen earnings volatility, while higher messaging costs and reliance on partners such as Shopify add real risk. The stock trades below one widely cited fair value estimate and has active buybacks, which together indicates that some investors may view the current valuation as conservative relative to the company’s ongoing product rollout and margin initiatives.
Klaviyo’s accelerating AI roll out and broadening product suite could be masking where expectations really sit. See how the analyst forecasts for Klaviyo ties together customer spend, valuation and one underappreciated pressure point.
The three stocks in this article are only a starting point, and the full Fast Growing Stocks With High Insider Ownership screener on Simply Wall St surfaced 172 more companies with similarly compelling narratives through the Fast Growing Stocks With High Insider Ownership screener. Use the platform to identify, analyze and filter for the specific catalysts and insider aligned stories that matter most to you, so you can focus on your highest conviction ideas.
Take Control of Your Investment Journey
If Klaviyo or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.
Seeking Fresh Alternatives Before They Fly
New breakout stories and quietly building momentum rarely stay under the radar for long. Spot the ideas others miss while it still matters and get in early.
- Target reliable cash generators that can handle shocks with a curated list of solid balance sheet and fundamentals (46 results) to keep you focused on resilience before the crowd catches on.
- Explore accelerating trends in automation using the hand picked 34 robotics and automation stocks to see which operators might be building momentum while expectations remain reasonable.
- Identify potential yield workhorses early through a refined 8 dividend fortresses that highlights income opportunities before payouts or prices move in response to increased interest.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Corcept Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com